Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amyloid and Tau PET in Multiple Sclerosis
NCT04242056Phase 2Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Feb 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of florzolotau in multiple sclerosis (MS), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Correlation between hyperintensity lesions in FLAIR MRI and demyelination in amyloid PET image at 3 years. Status: unknown.
02
Drugs
florzolotau
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04242056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242056.